AN OPEN LABEL RANDOMISED PHASE II STUDY COMPARING AZD2014 VERSUS EVEROLIMUS IN PATIENTS WITH ADVANCED METASTATIC RENAL CANCER AND PROGRESSION ON VEGF TARGETED THERAPY

Trial Profile

AN OPEN LABEL RANDOMISED PHASE II STUDY COMPARING AZD2014 VERSUS EVEROLIMUS IN PATIENTS WITH ADVANCED METASTATIC RENAL CANCER AND PROGRESSION ON VEGF TARGETED THERAPY

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2016

At a glance

  • Drugs Vistusertib (Primary) ; Everolimus
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Acronyms ZEBRA
  • Most Recent Events

    • 25 May 2015 According to results presents at 2015 Genitourinary Cancers Symposium, this study was stopped early (May 2014) at this point efficacy data for PFS favoured everolimus (n=40).
    • 23 Jun 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 23 Jun 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top